Patients will be included if they are aged 18 years or older,
with biopsy proven NSCLC,
clinically staged T3-T4 marginally resectable i.e. deemed at risk to achieve \<R0 resection (such as invasion of critical mediastinal or hilar structures, nodal extra-capsular extension, chest wall, vertebral bodies, compromised bronchial stump margin, based on CT images of the chest).
Patients also need to be pathologically staged N0-1 disease,
with an SBRT CTV≤200cm3, based on planning CT images.
ECOG status is required to be \<2 within 4 weeks prior to registration and
patients must be deemed medically operable by the surgical team.
You may not be if
Patients will be excluded if they are deemed medically inoperable by the surgical team
and have a weight loss of ≥10% within 3 months prior to pathological diagnosis.
Patients will also have no absolute contraindication to RT such as connective tissue disease, pacemaker-dependent patient with the pacemaker receiving higher than tolerance dose, had no had previous RT to the current region of the study, that would result in overlap of RT fields,
patients must have no plans to receive other local therapy while on study, except at disease progression,
patients have not had other malignancy within 2 years prior to the study (other than non-melanomatous skin cancers)
Clareo Health | Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection
